1. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression;Aguilar;Ann. Oncol.,2019
2. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase III KEYNOTE-598 study;Boyer;J. Clin. Oncol.,2021
3. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%;Brahmer;Ann. Oncol.,2020
4. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N. Engl. J. Med.,2017
5. Abstract CT084: Relationship Between STK11 and KEAP1 Mutational Status and Efficacy in KEYNOTE-042: Pembrolizumab Monotherapy Versus Platinum-Based Chemotherapy as First-Line Therapy for PD-L1-Positive Advanced NSCLC;Cho,2020